**Synthesis of Delgocitinib**

**Significance:** Delgocitinib is a Janus kinase inhibitor that has been approved in Japan for the treatment of atopic dermatitis. The FDA has granted Fast Track Designation to delgocitinib cream for the treatment of adult moderate-to-severe chronic hand eczema.

**Comment:** The route to delgocitinib depicted delivered the API in 39% overall yield in nine steps without recourse to cryogenic conditions or chromatographic purification. This route has been implemented on a 60 kg scale.

**Delgocitinib white solid**

---

**SYNFACTS Contributors:** Philip Kocienski

Synfacts 2021, 17(05), 0479 Published online: 20.04.2021

DOI: 10.1055/s-0040-1719790; Reg-No.: K02021SF

© 2021, Thieme. All rights reserved. Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany